FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
People may well compare car performance figures before buying, but I doubt many patients even think of doing so when it comes to medicines and drugs. The reason is that they trust the regulators (and their doctor) to ensure that all products work properly on the market. But why should a regulator of medicines be better than any other bureaucrat in any other field?
Are American patients taking unsafe medicines from Asia? Even posing that question is leading to unusually public confrontations between scientists and physicians on one side and the Food and Drug Administration on the other.
There is a growing concern that American patients are unknowingly being given unsafe medicines from overseas. Yet with nearly 3 billion prescriptions filled every year in the United States, everyone agrees that the U.S. drug supply is generally safe.
The drug quality lapses in India—which supplies more drugs to the United States than any other country—have become so unnerving that U.S. physicians are for the first time publicly voicing concern.
Tanzanian authorities and INTERPOL have just made a major seizure of fake and substandard drugs. While good news, it's a stark reminder that Africa remains ground zero in the global war on bad medicine.
Evidence is mounting that some pharmaceutical manufacturers in countries like India cut corners and send low-quality products to major, developed markets. Worse still, they may have separate production lines for drugs they sell in developing markets like Africa, where poor quality is more likely to go unnoticed.
Substandard and falsified medicines are major global health challenges that cause unnecessary morbidity and mortality around the world and threaten to undermine recent progress against infectious diseases by facilitating the emergence of drug resistance.
Please join AEI as the chief actuary for Medicare summarizes the report’s results, followed by a panel discussion of what those spending trends are likely to mean for seniors, taxpayers, the health industry, and federal policy.
Please join us as four of Washington’s most distinguished political observers will revisit the Watergate hearings and discuss reforms that followed.